Navigation Links
OrbusNeich's Genous™ Stent is Safe and Effective in Cases Where Prolonged Dual Antiplatelet Therapy is Not Advisable as Presented at EuroPCR 2011
Date:5/19/2011

us Stent is a good option for patients with relative contraindications to DES, as shown in these presentations and other recent studies, including the publication of the full dataset from the global e-HEALING registry in EuroIntervention this February," said Prof. Silber. "The body of evidence continues to grow in support of safety and effectiveness of the Genous EPC capture technology for treating these challenging cases."

About Genous  

Genous is OrbusNeich's patented EPC capture technology that promotes the accelerated natural healing of the vessel wall after the implantation of blood-contact devices such as stents. The technology consists of an antibody surface coating that attracts EPCs circulating in the blood to the device to form an endothelial layer that provides protection against thrombosis and modulates restenosis.

The Genous Stent, which has been commercially available in more than 60 countries since 2005, has been proven as a safe, effective alternative to drug eluting stents and is supported by data from more than 6,000 patients in company-sponsored clinical studies. There is a growing body of evidence from multiple clinical studies that the Genous Stent is effective for patients who are non-responsive to or cannot tolerate long-term dual antiplatelet therapy.

About OrbusNeich

OrbusNeich is a global company that designs, develops, manufactures and markets innovative medical devices for the treatment of vascular diseases. Current products are the world's first pro-healing stent, the Genous Stent, as well as other stents and balloons marketed under the names of Azule™, R stent, Scoreflex™, Sapphire™, Sapphire II and Sapphire NC. Development stage products include the Combo™ Bio-engineered Sirolimus Eluting Stent, or Combo Stent, which combines the Genous pro-healing technology for rapid endothelial coverage with an abluminal sirolimus drug elution for the control of neo
'/>"/>

SOURCE OrbusNeich
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Data Show OrbusNeichs Genous™ Bio-engineered R stent™ is Safe and Effective in Combination with Drug-Eluting Balloon
2. 100 Percent Coverage of Struts and Complete Neointimal Coverage of OrbusNeichs Genous™ Bio-engineered R stent™ Demonstrated 26 Days Post-Implantation in STEMI Patient
3. OrbusNeichs Genous™ Bio-engineered R stent™ Shows Favorable Safety Profile and Clinical Outcomes in Combination with Paclitaxel-Coated Balloon for De Novo Coronary Artery Disease
4. Data from Multiple Clinical Trials of OrbusNeichs Genous™ Bio-engineered R Stent™ Demonstrate Safety and Effectiveness Across Challenging Patient Subsets as Presented at TCT 2010
5. Randomized Clinical Trial of OrbusNeichs Genous™ Bio-engineered R stent™ in China Completes Patient Enrollment
6. OrbusNeichs Genous™ Stent Shows Favorable Outcomes for Treatment of Coronary Artery Bifurcation Lesions Compared to Bare Metal Stents
7. OrbusNeich Granted Expanded U.S. Patent of Genous™ Endothelial Progenitor Cell Capture Technology
8. Safety and Efficacy of OrbusNeichs Genous™ Stent Demonstrated in High-Risk Patients with Known Contraindications for Dual Antiplatelet Therapy
9. Published Data From e-HEALING Registry Demonstrate Good Clinical Outcomes With Low Incidence of Repeat Revascularization and Stent Thrombosis for OrbusNeichs Genous™ Stent
10. Data Published in the Journal of Interventional Cardiology Demonstrate Effectiveness and Safety of OrbusNeichs Genous™ Stent in Diabetic Patients
11. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... SAN ANTONIO, Texas , Sept. 18, 2014  Casen ... vessels, skin and muscles to harden.  His case is one ... (GVM) in the world.  The only hospital in ... few in the world, offering treatment with the dual wave-length ... in San Antonio . Using a laser ...
(Date:9/18/2014)... LONDON , Sept. 18, 2014 ... companies. Competition for innovation, increasing clinical development costs, ... with the fast-changing environment are important factors driving ... and clinical trial costs continue to rise due ... Studies conducted by industry think tanks suggest ...
(Date:9/18/2014)... NORTHVALE, N.J. , Sept. 18, 2014 /PRNewswire/ ... Gianluca DeNovi , Ph.D. to its corporate ... DeNovi is an instructor at the Harvard Medical ... Bio-Medico of Rome.  He received his Masters degree ... and Control Systems from the University of Bologna. After ...
Breaking Medicine Technology:Methodist Children's Hospital In San Antonio, TX Only Hospital In The U.S. Treating Rare Vascular Condition With Dual Wave-Length Laser 2Patient Recruitment in Asia Biotech and Pharma Companies 2Patient Recruitment in Asia Biotech and Pharma Companies 3ADM Tronics Appoints Gianluca DeNovi, Ph.D. To Advisory Board 2ADM Tronics Appoints Gianluca DeNovi, Ph.D. To Advisory Board 3
(Date:9/18/2014)... 18, 2014 (HealthDay News) -- Daily supplements of selenium ... the development of age-related cataracts among men, a new ... one or both could help prevent cataracts. To investigate ... and Harvard Medical School in Boston, and his colleagues ... and vitamin E. The trial was initially designed to ...
(Date:9/18/2014)... TayganPoint Consulting Group, a leading strategic ... co-founder John Cassimatis was named as one of ... recognizing the region’s top healthcare and life science ... the year. , The Innovation Awards celebrate companies ... to shape the medical industry in Greater Philadelphia ...
(Date:9/18/2014)... Stealth Health Revolution co-founders, Montel ... Frank Davis, founder of Food for Health International ... to announce the new recipe book, "The Simple ... meals using Activz whole-food powders." The Simple ... the Stealth Health Revolution mission to ...
(Date:9/18/2014)... companies can expect to pay higher employee contributions for ... human resource officers about the impact of the Patient ... or Obamacare) conducted by the Darla Moore School of ... May/June. , Patrick Wright, a professor in strategic human ... Chief HR Officers. The survey is distributed to more ...
(Date:9/18/2014)... develop tools that would allow them to clearly view ... neuron fires to the resulting behavior in a whole ... to develop a range of new tools to study ... tool that provides a new way of mapping neural ... between Viviana Gradinaru (BS ,05), assistant professor of biology ...
Breaking Medicine News(10 mins):Health News:Vitamin E, Selenium Supplements Don't Seem to Prevent Cataracts 2Health News:TayganPoint Executive Receives Prestigious Award from Philadelphia Business Journal 2Health News:Montel Williams and Frank Davis Announce New Whole-Food Nutrition Recipe Book, The Simple Scoop, at Natural Products Expo East In Baltimore 2Health News:Montel Williams and Frank Davis Announce New Whole-Food Nutrition Recipe Book, The Simple Scoop, at Natural Products Expo East In Baltimore 3Health News:Survey: Fortune 500 employees can expect to pay more for health insurance 2Health News:Survey: Fortune 500 employees can expect to pay more for health insurance 3Health News:Sensing neuronal activity with light 2Health News:Sensing neuronal activity with light 3Health News:Sensing neuronal activity with light 4Health News:Sensing neuronal activity with light 5
... May 13th at Long Beach Veterans Administration Hospital, ... West Hills/Northridge,Veterans Administration will honor Dr. Richard Merkin, ... the health of American,war veterans. The VA, in ... a clinical research study aimed at,examining diabetic ulcers ...
... Colo., April 24 Heska Corporation,(Nasdaq: HSKA ) announces the following Webcast:, ... Earnings Conference Call on the Web, ... (click on the Q1 2008 Earnings Call link on ... Live over the Internet -- Simply log on to the web at the address ...
... Members, Elect New Member to Board, Reject ... Stockholder Proposals - ... -, MADISON, N.J., April 24 At today,s Annual,Meeting of Stockholders ... 12 current members of the Company,s Board of,Directors and elected nominee Michael ...
... David B. Snow,Jr., chairman & chief executive officer ... scheduled to address the Morgan Stanley Global Healthcare,Unplugged Conference ... The presentation at the Ritz-Carlton, Key Biscayne, will begin ... financial officer, is also,scheduled to attend., The presentation ...
... New Call Center, WASHINGTON, April 24 On ... contacting nearly 570,000,recent combat veterans to ensure they know ... reach out and touch every veteran of Operation Enduring,Freedom ... are here for them,",said Dr. James B. Peake, Secretary ...
... concepts through abstract cases more likely to retain knowledge, ... The use of "real-world" concrete examples doesn,t help students ... that challenges the widespread use of this approach in ... who learned a mathematical concept with concrete examples couldn,t ...
Cached Medicine News:Health News:Veterans Honor Dr. Richard Merkin During Research Week 2Health News:Webcast Alert: Heska Announces First Quarter 2008 Earnings Conference Call Webcast 2Health News:Wyeth Holds Annual Meeting of Stockholders 2Health News:Wyeth Holds Annual Meeting of Stockholders 3Health News:Wyeth Holds Annual Meeting of Stockholders 4Health News:Medco CEO to Present at the Morgan Stanley Global Healthcare Unplugged Conference 2Health News:VA Calling All Recent Combat Vets 2Health News:'Real World' Examples Don't Make Math Any Easier 2
Cross action, round handle, maximum opening 2.8 mm....
Irrigating nucleus chopper, tip angled 30 to side wedge shaped inferior edge with blunt tip and front notch for engaging iris end opening, 19 gauge. For use in the right hand....
Irrigating nucleus chopper, wedge-shaped inferior edge with, blunt tip, 0.6 mm dual sideports, 20 gauge....
Irrigating nucleus chopper, semi-sharp, wedge shaped inferior edge with a pointed tip, dual sideports, 20 gauge. For Phakonit cataract surgery....
Medicine Products: